Work Here?
Overview
Vedanta Biosciences develops drugs based on bacterial consortia (groups of bacteria working together) to treat diseases. Using a proprietary discovery platform, the company identifies beneficial bacteria and designs rational consortia with optimized therapeutic activity, which can colonize the human intestine. The drugs are produced under CGMP standards for commercial-scale manufacturing. Unlike many biotech efforts that focus on single strains, Vedanta emphasizes defined bacterial consortia and scalable production to bring microbiome therapies to patients. Its goal is to develop and commercialize microbiome-based drugs that provide new treatment options for a range of diseases.
About Vedanta Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$374.7M
Headquarters
Cambridge, Massachusetts
Founded
2010
Simplify's Take
What believers are saying
- VE303 Phase 3 RESTORATiVE303 enrollment across 200+ sites in 24 countries progressing.
- Regulatory clarity for live biotherapeutic products establishing precedent for future LBP approvals.
- Antimicrobial resistance funding mechanisms like CARB-X provide alternative capital sources beyond venture.
What critics are saying
- VE202 Phase 2 ulcerative colitis failure signals potential VE303 Phase 3 efficacy risk.
- Seres Therapeutics' VOWST captured rCDI market with FDA approval since 2023.
- PureTech Health divestment or support termination halts critical Phase 3 financing.
What makes Vedanta Biosciences unique
- Rationally-designed bacterial consortia with proprietary discovery platform and cGMP manufacturing capabilities.
- Fast Track FDA designation for VE303 in recurrent C. difficile infection prevention.
- Microbiome-based immuno-oncology expansion potential demonstrated through Bristol-Myers Squibb collaboration.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$374.7M
Above
Industry Average
Funded Over
10 Rounds
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 6%2 year growth
↑ 5%About a year after that fundraise, a dip in manufacturing needs prompted Vedanta to lay off 24 employees.
VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection (CDI). CAMBRIDGE, MA, May 21, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application (BLA) to be filed with the U.S. Food and Drug Administration
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study of VE303, which is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application to be filed with the U.S. Food and Drug Administration. The full text of the announcement from Vedanta is as follows:. Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application (BLA) to be filed with the U.S. Food and Drug Administration. “Initiation of the RESTORATiVE303 study represents a key clinical milestone for the VE303 program
Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Ac
Vedanta Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Vedanta Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$374.7M
Headquarters
Cambridge, Massachusetts
Founded
2010
Vedanta Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today